Stryker Reports Q3 2026 Results with 7.7% Organic Sales Growth Amid Orthopaedic Headwinds
Stryker (SYK) reported third-quarter organic sales growth of 7.7%, driven by strong performance in its MedSurg, Neurotechnology, and Orthopaedics segments. Adjusted earnings per share rose 10.3% to $3.52, supported by gross margin expansion to 65.4% and disciplined expense management. The company also demonstrated strong cash flow, reporting $3.3 billion in cash from operations year-to-date. Despite the overall growth, Stryker faces challenges in its U.S. Orthopaedics segment, specifically within hip and knee reconstruction. Management cited macroeconomic pressures, including higher insurance premiums, deductibles, and increased pre-authorization denials, as primary drivers for a slowdown in these procedures. Consequently, the company has revised its full-year organic sales guidance downward to a range of 6.5% to 7.0%. To support shareholder value, Stryker repurchased $1 billion in stock during the quarter and received board authorization for an additional $3 billion in future share repurchases.
Topics: Adjusted EPS Gross Margin Expansion Guidance Revision MedTech Segment Performance Organic Sales Growth
Read the full article at Motley Fool
Part of the story AptarGroup Reports Q3 2026 Sales Growth Amidst Margin Compression and Russian Deconsolidation (3 articles)